BriaCell to Showcase Favorable Clinical Biomarker Results from Phase 3 Study at ESMO 2025
Clinical Study Findings: BriaCell's ongoing Phase 3 study of Bria-IMT in metastatic breast cancer shows that positive delayed-type hypersensitivity (DTH) is significantly associated with longer progression-free survival (PFS), with no new safety issues reported.
Presentation at ESMO Congress: The company will present positive clinical biomarker data at the ESMO Congress 2025, highlighting the efficacy of Bria-IMT combined with an immune checkpoint inhibitor in improving patient outcomes.
Trade with 70% Backtested Accuracy
Analyst Views on BCTXZ
No data
About the author
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.
Financial Details: The offering raised a total of US$30 million.
BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025
BriaCell's Presentations at SABCS: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.
Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.
Poster Presentation Details: Key presentations include topics on the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.
Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.
